A team of scientists from Tubingen Institute of Tropical Medicine, and German company Deutschen Malaria GmbH, discovered a new combinational medicine which could effectively cure malarial without any side effects
This is the second partnership of the firm, the first outside oncology. It has a USD 790 million collaboration signed in 2016 with drugmaker Takeda of Japan. The deal with Zai Lab is the first for Crescendo to involve a specific pipeline asset. The deal with Takeda was more of a platform agreement giving it the required confidence to collaborate with other programs in oncology.
A research team from Italy reported that a glance of light might provide relief from pain. They first identified the oversensitive nerve cells that cause chronic pain. Then, a light-sensitive chemical was developed and injected, which binds to these nerve cells. Next, a flash of near-infrared light was passed to the exact nerve in order to provide instant pain relief. This strategy was experimentally proved in mice.
A research team from the University of Ottawa in Canada revealed a safe and inexpensive treatment by employing Viagra and flu vaccines that might stop cancer revival. Tadalafil (Cialis), sildenafil (Viagra) in combination with Agriflu were used in the research work.
The research study revealed that tumor growth could be reduced by targeting the expression of Beta3-integrin along with microtubule-targeting agents (MTAs) chemotherapy. Beta3-integrin was the better anti-angiogenic target since it was expressed in tumor blood vessels, unlike normal cells.
The company announced that the innovative product, whose technological details are not known yet, is undergoing clinical trials in five cities across the world. The patent-pending invention is based on open standards software and cloud-based analytics. The system gives users real-time notifications and cloud-based AI solutions.
A research team led by Yokohama City University and Toyama Chemical Co Ltd in Japan has developed a small compound named edonerpic maleate that showed enhanced recovery of motor function after brain damage in animal trials.
EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.